EP0268647A1 - A method of sequencing nucleic acids - Google Patents
A method of sequencing nucleic acidsInfo
- Publication number
- EP0268647A1 EP0268647A1 EP87903715A EP87903715A EP0268647A1 EP 0268647 A1 EP0268647 A1 EP 0268647A1 EP 87903715 A EP87903715 A EP 87903715A EP 87903715 A EP87903715 A EP 87903715A EP 0268647 A1 EP0268647 A1 EP 0268647A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dna
- membrane
- nucleic acids
- sequencing
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 19
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 19
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 19
- 238000012163 sequencing technique Methods 0.000 title claims abstract description 16
- 239000012528 membrane Substances 0.000 claims abstract description 37
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 8
- 238000000746 purification Methods 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 238000011065 in-situ storage Methods 0.000 claims abstract description 4
- 239000000725 suspension Substances 0.000 claims abstract description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 12
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 239000004365 Protease Substances 0.000 claims description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 229940088598 enzyme Drugs 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 210000004777 protein coat Anatomy 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 4
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001962 electrophoresis Methods 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 108090000317 Chymotrypsin Proteins 0.000 claims description 3
- 239000000020 Nitrocellulose Substances 0.000 claims description 3
- 230000000593 degrading effect Effects 0.000 claims description 3
- 229920001220 nitrocellulos Polymers 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000001712 DNA sequencing Methods 0.000 claims description 2
- 230000000274 adsorptive effect Effects 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 abstract description 4
- -1 DNA Chemical class 0.000 abstract description 2
- 230000007717 exclusion Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 30
- 235000019419 proteases Nutrition 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Procédé de mise en séquence d'acides nucléiques, tels que l'ADN, qui élimine les étapes de centrifugation pendant la purification avant la mise en séquence, qui réduit la manipulation des produits extraits et qui se prête à l'automatisation. Ce procédé consiste en une étape de purification comprenant la séparation, activée par la pression, de l'ADN ou de l'ARN à partir d'une suspension de digestat par ultrafiltration en utilisant une membrane filtrante qui retient les acides nucléiques et les présente dans un état permettant le début immédiat de la séquence de détermination in situ sur la membrane. La membrane filtrante peut retenir des acides nucléiques par exclusion selon la taille et/ou adsorber des acides nucléiques par liaison superficielle.A method of sequencing nucleic acids, such as DNA, which eliminates centrifugation steps during purification before sequencing, which reduces handling of the extracted products and which is suitable for automation. This process consists of a purification step comprising the separation, activated by pressure, of DNA or RNA from a digestate suspension by ultrafiltration using a filter membrane which retains the nucleic acids and presents them in a state allowing the immediate start of the determination sequence in situ on the membrane. The filter membrane can retain nucleic acids by exclusion depending on the size and / or adsorb nucleic acids by surface bonding.
Description
A method of sequencing nucleic acids. The present invention relates to an improved method of sequencing nucleic acids, and particularly but not exclusively to an improved method of sequencing DNA. The technique of nucleotide sequence analysis is of central importance in molecular biology and biotechnology. Contemporary methods of sequencing are mostly based on the high resolving power of polyacrylamide-gel electrophoresis. By this technique two oligonucleotides which differ in size by only a single nucleotide residue can be resolved by virtue of their differing relative interactions with the gel matrix. Alternative resolving methods are currently being investigated, for example column based systems such as high pressure liquid chromatography (HPLC). In order to determine the sequence of nucleotides in a nucleic acid such as DNA a series of fragments are produced with one end in common and the other varying in position along the chain. A minimum of four types of series of fragments is produced, each group being terminated by or cleaved at one of the four possible bases by specific chemical or enzymic means. There are two well known ways in which DNA fragments ending in or cleaved at each of the four bases are produced for sequence analysis. In the method described by Maxam and Gilbert (reference 1 and 2) single- or double-stranded DNA molecules are labelled with radioactive 32P phosphate at a unique 5' or 3' terminus and the nucleotide chains are chemically 8modified at specific bases and then cleaved by alkaline or piperidine hydrolysis. The chain termination method of Sanger et al (reference 3 to 6) involves enzymic copying of single-stranded DNA fragments using a DNA polymerase to transcribe specific regions of the chain under controlled conditions. In both the above described methods it is necessary to extract and purify the nucleic acids prior to initiating sequencing reactions. Conventionally RNA and DNA from tissues, cells, plasmids and viruses are extracted and purified by lysis or digestion of the protein coat (e.g. with a protease - such as proteinase K - which is able to digest the protein coat without degrading the nucleic acids) followed by extraction with solvent, such as phenol-chloroform, and precipitation with e.g. ethanol. Separation of nucleic acids from suspension in solvents is achieved by repeated centrifugation. The phenol-chloroform reagent is a toxic corrosive liquid which is unpleasant to handle. After extraction with phenol-chloroform it is necessary to separate the aqueous from the organic phase. Centrifugation steps in the extraction/purification procedures are time consuming and tedious when carried out manually, and are difficult to automate satisfactorily. The present invention provides an improved method of sequencing nucleic acids, such as DNA, which eliminates centrifugation steps during pre-sequencing purification, reduces manipulation of extracted products and is suitable for automation. According to the invention, the improvement resides in a purification step which comprises the pressure activated separation of DNA or RNA from a digest suspension by ultrafiltration using a filter membrane which retains the nucleic acids and presents them in a state ready for immediate commencement of sequence determination in situ on the membrane. The filter membrane may (a) retain nucleic acids by size exclusion andlor may (b) adsorb nucleic acids by surface binding. Examples of filter membranes of type (a) are anisotropic low absorptive ultrafiltration membranes such as the type-YM membranes marketed by Amicon Corporation (US Patent No. 3488768). Examples of filter membranes of type (b) are nitrocellulose membranes, NA45(Th), DE81(TM), Genescreen (tri), Hybond (tri) and the like; filter membranes having non-specific binding sites may be partially blocked with Bovine Serum Albumin (BOA) or other inert material. An advantage of using nltrafiltration for separation and purification of nucleic acids is that the material collected on the membrane can be further treated in situ. For example, chemical or enzymic reagents can be applied to the membrane surface after filtration in order to prepare the trapped nucleic acids for sequencing. The method of the invention can be used in an improved enzymic sequencing process including the following steps: 11 A vector carrying a DNA insert to be sequenced is cultured in a host, 2] vector particles containing the DNA inserts are separated from the host by filtration, 3 ] a protease is applied which will digest the protein coat of the vector without degrading the DNA, 4 ] the DNA is purified and concentrated by pressure activated ultrafiltration through a membrane which retains the DNA, 5 ] primer is added and annealed to the extracted DNA on the membrane, 6 ] a polymerisation enzyme together with a suitable nucleotide mixture is applied to the DNA on the membrane, the enzyme being one which is capable of catalysing the faithful incorporation of nucleotides onto a primed template, 7] chase nucleotides are added if necessary in order to complete the polymerisation reaction, 81 the reaction is terminated and the newly synthesized DNA is disassociated from the template, and 9] a sample of DNA is loaded onto a polyacrylamide gel for electrophoresis, or onto an alternative separation system. In the above described method any host/vector system can be used in which vector DNA is released from the host cell, generally in the form of a protein coated particle. The DNA could be single or double stranded; if the DNA is double stranded a denaturation step must be included before annealing in order to separate the strands. The chosen vector must have been manipulated so as to carry both the DNA fragment to be sequenced and the appropriate primer hybridisation site. A particularly suitable host is the bacterium E.Coli, and suitable vectors are bacteriophage M13, plasmid pEMBL and F1 derived vectors. Examples of suitable protease are chymotrypsin, elastase, subtilisin and thermolysin. Residual protease activity can be terminated after the reaction has proceeded to completion by use of an ethanol wash or a protease inhibitor. Alternatively, the protease may have autolytic activity and hence be self-terminating. The catalysis enzyme is preferably a DNA polymerase such as a Klenow fragment of DNA polymerase I or reverse transcriptase. The enzyme must not have exonuclease activity which would digest the primer; if present, exonuclease activity can be blocked by the addition of a blocking group at the 5' end of the molecule. If the above described method were adapted for sequencing with ribonucleotides, then ribonucleotides would be used instead of deoxyribonucleotides in the polymerisation step. In such a case an appropriate RNA polymerase would be used, possibly without the need for a primer. Alternatively, if a suitable vector for RNA were developed, RNA could be used as the template. One embodiment of the invention will now be described in detail, by way of example only. The Example illustrates an improved method of DNA sequencing using the chain termination method described by Sanger. EXAMPLE The method comprises the following steps 1) Bacteriophage M13 with a DNA insert is cultured overnight in E.Coli in suitable culture medium. 2) The bacteria are separated from the phage by filtration with a 0.22 micron membrane, such as hydrophilic Durapore (Millipore). The bacteria remain on the filter and the DNA-carrying phage pass through the membrane into a collection vessel. 3) The phage are incubated with a protease, such as chymotrypsin, in order to digest the protein coat. 4) The DNA from the phage is separated from the digested protein by pressure activated ultrafiltration through a membrane which retains the DNA but not the digested protein. A preferred sizeexclusion membrane is YH10 (Amicon) which retains globular molecules of size greater than 10 kDaltons. Alternatively, an adsorptive membrane such as nitrocellulose may be used. Non-specific binding of reagents to the filter can be prevented by the addition of 1 Z bovine serum albumin. 5) The primer is added as a droplet or a spray to the DNA on the filter membrane and is annealed for 20 minutes at 55 to 65eC to allow specific hybridisation. 6) Premixed nucleotides and DNA polymerase I Klenow fragment are added as a droplet or a spray to the filter membrane and are incubated at 200C for 15 minutes. The nucleotides are incorporated onto the primed template to synthesize DNA by chain extension. The nucleotides may include labelled nucleotides and chain terminating nucleotides. 7) Chase nucleotides are added if necessary. 8) A formamide droplet or spray is placed on the membrane and heated at 900C for 5 minutes in order to terminate reaction and caused disassociation of newly synthesized DNA from the template. 9) A DNA sample is loaded onto a conventional polyacrylamide gela 10) The DNA fragments are separated by electrophoresis. REFERENCES 1. ' Maxam, AM. and Gilbert, W (1977), Proc.Natl. Acad.Sci., USA., 74, 560-564. 2. Maxam, A.M. and Gilbert, W (1980), in Methods in Enzymology, (ed Wil, R), 68, p.499, Academic Press, London and New York. 3. Sanger, F. and Coulson, A.R. (1978), FEBS lett.,87, 107-110. 4. Sanger, F. and Coulson, A.R. (1975), J.Mol.Biol.,94, 441-448. 5. Sanger, F., Nicklen, S. and Coulson, A.R. (1977), Proc.Natl.Acad.Sci., USA,74, 5463-5467. 6. Air, G.M., Sanger, F. and Coulson, A.R. (1976), J.Mol.Biol. ,108, 519-533.
Claims
CLAIMS:
1. An improved method of sequencing nucleic acids wherein the improvement resides in a purification step which comprises the pressure activated separation of DNA or RNA from a digest suspension by ultrafiltration using a filter membrane which retains the nucleic acids and presents them in a state ready for immediate commencement of sequence determination in situ on the membrane.
2. An improved enzymic sequencing process for DNA which includes the following steps i] a vector carrying a DNA insert to be sequenced is cultured in a host, ii] vector particles containing the DNA inserts are separated from the host by filtration, iii] a protease is applied which will digest the protein coat of the vector without degrading the DNA, iv] the DNA is purified and concentrated by pressure activated ultrafiltration through a membrane which retains the DNA, v ] primer is added and annealed to the extracted DNA on the membrane, vi] a polymerisation enzyme together with a suitable nucleotide mixture is applied to the DNA on the membrane, the enzyme being one which is capable of catalysing the faithful incorporation of nucleotides onto a primed template,
vii] chase nucleotides are added if necessary in order to complete the polymerisation reaction, viii] the reaction is terminated and the newly synthesized DNA is disassociated from the template, and ix) a sample of DNA is loaded onto a polyacrylamide gel for electrophoresis, or onto an alternative separation system.
3. An improved method of DNA Sequencing using the chain termination method of Sanger, which includes the following steps a) Bacterophage M13 with a DNA insert is cultured in E.Coli in suitable culture medium, b) the bacteria are separated from the phage by filtration with a hydrophilic membrane, c) the phage are incubated with chymotrypsin protease, d) the DNA from the phage is purified and concentrated by pressure activated ultrafiltration through a membrane which retains the DNA (e.g.
a size-exclusion membrane which retains globular molecules of size greater than 10 kDaltons or an adsorptive membrane such as nitrocellulose), e) primer is added as a droplet or a spray to the DNA on the filter membrane and is annealed for 20 minutes at 55 to 650C, f) premixed nucleotides and DNA polymerase I Klenow fragment are added as a droplet or a spray to the filter membrane and are incubated at 200C for 15 minutes, g) chase nucleotides are added if necessary, h) a formamide droplet or spray is placed on the membrane and heated at 900C for 5 minutes, i) a DNA sample is loaded onto a polyacrylamide gel, and j) DNA fragments are separated by electrophoresis.
4. An improved method of sequencing, substantially as hereinbefore described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868613476A GB8613476D0 (en) | 1986-06-04 | 1986-06-04 | Method of sequencing nucleic acids |
| GB8613476 | 1986-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0268647A1 true EP0268647A1 (en) | 1988-06-01 |
Family
ID=10598881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP87903715A Withdrawn EP0268647A1 (en) | 1986-06-04 | 1987-06-03 | A method of sequencing nucleic acids |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0268647A1 (en) |
| JP (1) | JPH01500482A (en) |
| GB (1) | GB8613476D0 (en) |
| WO (1) | WO1987007645A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8801070D0 (en) * | 1988-03-23 | 1988-03-23 | Pharmacia Ab | METHOD FOR IMMOBILIZING A DNA SEQUENCE ON A SOLID SUPPORT |
| EP0340609A3 (en) * | 1988-05-06 | 1991-07-31 | F. Hoffmann-La Roche Ag | Device for the isolation of nucleic acids |
| WO1991011533A1 (en) * | 1990-01-26 | 1991-08-08 | E.I. Du Pont De Nemours And Company | Method for isolating primer extension products from template-directed dna polymerase reactions |
| DE4143639C2 (en) * | 1991-12-02 | 2002-10-24 | Qiagen Gmbh | Process for the isolation and purification of nucleic acids |
| GB9314249D0 (en) * | 1993-07-09 | 1993-08-18 | Proofname Ltd | Purification method and apparatus |
| US7026468B2 (en) | 1996-07-19 | 2006-04-11 | Valentis, Inc. | Process and equipment for plasmid purification |
| US7807822B2 (en) | 1996-08-01 | 2010-10-05 | Robert Bridenbaugh | Methods for purifying nucleic acids |
| US6011148A (en) * | 1996-08-01 | 2000-01-04 | Megabios Corporation | Methods for purifying nucleic acids |
| DE19746874A1 (en) * | 1997-10-23 | 1999-04-29 | Qiagen Gmbh | Isolation of nucleic acids |
| GB2346615B (en) | 1998-11-17 | 2003-10-15 | Cambridge Molecular Tech | Isolating nucleic acid |
| WO2000066723A1 (en) * | 1999-05-04 | 2000-11-09 | Millipore Corporation | Method of ultrafiltration |
| US6498240B1 (en) | 1999-09-17 | 2002-12-24 | Millipore Corporation | Method for sequencing reaction cleanup by constant pressure diffential ultrafiltration |
| WO2001094574A2 (en) * | 2000-06-07 | 2001-12-13 | Amersham Biosciences Corp | Method and apparatus for purifying nucleic acids |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3308932A1 (en) * | 1983-03-12 | 1984-09-13 | Hoechst Ag, 6230 Frankfurt | METHOD FOR SEPARATING RIBONUCLEIC ACIDS FROM A SOLUTION CONTAINING DESOXYRIBONUCLEIC ACIDS |
| SE451843B (en) * | 1983-05-09 | 1987-11-02 | Gambro Lundia Ab | PROCEDURE FOR EX recovering an association |
-
1986
- 1986-06-04 GB GB868613476A patent/GB8613476D0/en active Pending
-
1987
- 1987-06-03 JP JP62503392A patent/JPH01500482A/en active Pending
- 1987-06-03 EP EP87903715A patent/EP0268647A1/en not_active Withdrawn
- 1987-06-03 WO PCT/GB1987/000384 patent/WO1987007645A1/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO8707645A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH01500482A (en) | 1989-02-23 |
| GB8613476D0 (en) | 1986-07-09 |
| WO1987007645A1 (en) | 1987-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0406296B1 (en) | Method of sequencing dna | |
| US6969603B2 (en) | Method for isolating DNA | |
| US4446237A (en) | Method for detection of a suspect viral deoxyribonucleic acid in an acellular biological fluid | |
| US5484701A (en) | Method for sequencing DNA using biotin-strepavidin conjugates to facilitate the purification of primer extension products | |
| US5783686A (en) | Method for purifying nucleic acids from heterogenous mixtures | |
| EP0442026B1 (en) | Method to extract and purify human genomic DNA | |
| AU772213B2 (en) | Biochemical purification devices with immobilized capture probes and their uses | |
| CA2119140A1 (en) | Dna cycle sequencing | |
| EP0268647A1 (en) | A method of sequencing nucleic acids | |
| IE911508A1 (en) | Preparation and isolation of single-stranded, biotinylated¹nucleic acids by avidin-biotin cleavage | |
| DE19925862A1 (en) | Process for the synthesis of DNA fragments | |
| WO1994001447A1 (en) | Methods of single nucleotide primer extension to detect specific alleles and kits therefor | |
| EP0979868B1 (en) | Electrophoretic separation of nucleic acids from biological samples at low pH | |
| JPH03180182A (en) | Purification of phage dna | |
| WO2001062976A1 (en) | Rapid nucleic acid separation, isolation and purification methods | |
| EP1218076B1 (en) | Method for sequencing reaction cleanup by constant pressure differential ultrafiltration | |
| EP1144692B1 (en) | Method for separating nucleic acids into populations | |
| JPH0341087A (en) | Purification, multiplication and detection of nucleic acid | |
| US20030228600A1 (en) | DNA isolation method and kit | |
| EP0278513A2 (en) | Process of preparing single-stranded DNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
| 17P | Request for examination filed |
Effective date: 19880613 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19910103 |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: COATES, ANTHONY, ROBERT, MILNES Inventor name: HALL, LUCINDA, MARY, CLARE Inventor name: BLENCH, IAN |